<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fifty-eight cases diagnosed as malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in patients younger than 15 years between 1976 and 1986 in the Kanto area were reviewed and reclassified as follow: 48 non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 9 Hodgkin's disease and one malignant <z:mpath ids='MPATH_146,MPATH_652'>histiocytosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>Lymphoblastic type consisted of 26 cases or 54.2%; large cell type, 11 cases or 22.9%; Burkitt's type, 7 cases or 14.5%; medium-sized cell type and mixed cell type consisted of 4 cases </plain></SENT>
<SENT sid="2" pm="."><plain>There was no follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> case </plain></SENT>
<SENT sid="3" pm="."><plain>A rare sclerosing mediastinal lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and diffuse large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with T-zone involvement as well as primary epidural Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were found </plain></SENT>
<SENT sid="4" pm="."><plain>Immunohistochemical studies using paraffin sections were performed in 43 non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and phenotypes of 37 cases were determined as follows; T cell origin in 24, B cell origin in 11 and non-T non-B in 2 cases </plain></SENT>
<SENT sid="5" pm="."><plain>Of 25 lymphoblastic <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, LCA was positive only in 11 cases </plain></SENT>
<SENT sid="6" pm="."><plain>Reed-Sternberg cells and their variants of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> reacted with anti-Leu M1 antibody in 3 of 8 examined but not with EMA antibody </plain></SENT>
<SENT sid="7" pm="."><plain>This study revealed that the survival was related to sites of the <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesion</z:e>, regardless of histological type and immunologic phenotypes </plain></SENT>
</text></document>